Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo. Additionally, 36.8% of those treated with Ozempic experienced improvement in liver fibrosis versus 22.4% of the placebo group.

A new study published in the New England Journal of Medicine reveals that medications widely used for diabetes and obesity may offer significant benefits for patients with liver disease, adding to the growing list of potential applications for these popular drugs.